EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Prophylaxis against Pneumocystis jirovecii pneumonia and toxoplasmosis with low-dose Trimethoprim-sulfamethoxazole (cotrimoxazole 20/100 mg) in heart transplant patients. The PAPTO-LOCO observational comparative study

Dahlia Aggoun, Constance Verdonk, Alexandre Bleibtreu iD, Arnaud Fekkar iD, Sandrine Houze, Lara Zafrani, Eva Desire, Shaida Varnous, Pascal Leprince, Guillaume Coutance, Mickael Lescroart iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf087 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Dahlia Aggoun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University Medical School, Paris, Franc…. Hauptthemen laut MEDLINE: Heart Transplantation, Trimethoprim, Sulfamethoxazole Drug Combination, Pneumonia, Pneumocystis, Toxoplasmosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Practice concerning post-transplant Pneumocystis prophylaxis remains heterogeneous. SXT benefits must be balanced with frequent toxicity. We aimed to assess whether a low-dose SXT strategy might limit toxicities while maintaining an undisrupted prophylaxis compared with a standard dose in a retrospective cohort of heart transplant population.

Methods

Patients undergoing heart transplant from two distinct centres, receiving daily SXT 20/100 mg versus daily SXT 80/400 mg between 2018 and 2020, were retrospectively included in the study. Demographic, immunosuppression and survival characteristics were collected to ensure group comparability. The occurrence of adverse effects and the rate of SXT discontinuation were compared between the two groups.

Results

Overall, 359 patients were recruited in the study, 108 patients for the standard-dose group and 251 patients for the low-dose group. The leading cause of prophylaxis discontinuation was cytopenia. We observed significantly more discontinuation in the standard-dose compared with the low-dose group (24.1% and 6.4%, respectively, P < 0.001). No patient with ongoing prophylaxis presented Pneumocystis pneumonia or toxoplasmosis during the 2-year follow-up. Two Pneumocystis infections in the low-dose group occurred during prophylaxis breaks. The rate of toxoplasmosis seroconversion was similar in both groups.

Conclusions

This retrospective study suggests that a low-dose SXT Pneumocystis prophylaxis strategy might offer a more favourable safety/efficacy profile than standard-dose prophylaxis after heart transplantation. These results should be confirmed in an interventional trial. Caution remains for toxoplasmosis serology D+/R− profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart TransplantationTrimethoprim, Sulfamethoxazole Drug CombinationPneumonia, PneumocystisToxoplasmosisAntibiotic ProphylaxisHumansMaleFemaleRetrospective StudiesMiddle AgedPneumocystis cariniiAdultAgedTransplant Recipients

Substanzen

Trimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University Medical School, Paris, France.
  • Department of Cardiac and Thoracic Surgery, Bichat Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
  • Infectious and Tropical Diseases Ward, Pitié-Salpêtrière Hospital, Paris, France.
  • Service de Parasitologie-Mycologie, APHP Sorbonne Université Hôpital Pitié-Salpêtrière, Paris 75013, France.
  • Laboratoire de Parasitologie-Mycologie, Bichat-Claude Bernard Hospital, APHP, University of Paris Cité, Paris, France.
  • Medical Intensive Care Unit, Saint-Louis Hospital, AP-HP, University of Paris Cité, Paris, France.

ORCID-Profile: Alexandre Bleibtreu, Arnaud Fekkar, Mickael Lescroart

Zitieren

APA

Aggoun, D., Verdonk, C., Bleibtreu, A., Fekkar, A., Houze, S., Zafrani, L., Desire, E., Varnous, S., Leprince, P., Coutance, G., & Lescroart, M. (2025). Prophylaxis against Pneumocystis jirovecii pneumonia and toxoplasmosis with low-dose Trimethoprim-sulfamethoxazole (cotrimoxazole 20/100 mg) in heart transplant patients. The PAPTO-LOCO observational comparative study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf087

Vancouver

Aggoun D, Verdonk C, Bleibtreu A, Fekkar A, Houze S, Zafrani L, et al. Prophylaxis against Pneumocystis jirovecii pneumonia and toxoplasmosis with low-dose Trimethoprim-sulfamethoxazole (cotrimoxazole 20/100 mg) in heart transplant patients. The PAPTO-LOCO observational comparative study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf087

BibTeX
@article{Aggoun2025,
  author = {Aggoun, Dahlia and Verdonk, Constance and Bleibtreu, Alexandre and Fekkar, Arnaud and Houze, Sandrine and Zafrani, Lara and Desire, Eva and Varnous, Shaida and Leprince, Pascal and Coutance, Guillaume and Lescroart, Mickael},
  title = {Prophylaxis against Pneumocystis jirovecii pneumonia and toxoplasmosis with low-dose Trimethoprim-sulfamethoxazole (cotrimoxazole 20/100 mg) in heart transplant patients. The PAPTO-LOCO observational comparative study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf087}
}
Kostenlos starten →